Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women.

Dowty JG, Lose F, Jenkins MA, Chang JH, Chen X, Beesley J, Dite GS, Southey MC, Byrnes GB, Tesoriero A, Giles GG, Hopper JL, Spurdle AB; kConFab Investigators; Australian Breast Cancer Family Study (ABCFS).

Breast Cancer Res Treat. 2008 Nov;112(1):35-9. Epub 2007 Dec 4.

PMID:
18058226
2.

Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population.

Jara L, Dubois K, Gaete D, de Mayo T, Ratkevicius N, Bravo T, Margarit S, Blanco R, Gómez F, Waugh E, Peralta O, Reyes JM, Ibáñez G, González-Hormazábal P.

Breast Cancer Res Treat. 2010 Aug;122(3):813-22. doi: 10.1007/s10549-009-0709-2. Epub 2010 Jan 7.

PMID:
20054644
3.

The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.

Rodríguez-López R, Osorio A, Ribas G, Pollán M, Sánchez-Pulido L, de la Hoya M, Ruibal A, Zamora P, Arias JI, Salazar R, Vega A, Martínez JI, Esteban-Cardeñosa E, Alonso C, Letón R, Urioste Azcorra M, Miner C, Armengod ME, Carracedo A, González-Sarmiento R, Caldés T, Díez O, Benítez J.

Int J Cancer. 2004 Jul 20;110(6):845-9.

4.

Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry.

Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P.

Hum Mutat. 2006 Nov;27(11):1122-8.

PMID:
16958054
5.

A PALB2 mutation associated with high risk of breast cancer.

Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes GB, Winship I, Baglietto L, Giles GG, Goldgar DE, Foulkes WD, Hopper JL; kConFab for the Beast Cancer Family Registry.

Breast Cancer Res. 2010;12(6):R109. doi: 10.1186/bcr2796. Epub 2010 Dec 23.

6.

Functional characterization of the RAD51D E233G genetic variant.

Nadkarni A, Furda A, Rajesh C, McInnes C, Ruch RJ, Pittman DL.

Pharmacogenet Genomics. 2009 Feb;19(2):153-60. doi: 10.1097/FPC.0b013e32831db2fd.

PMID:
19033885
7.

Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines.

Nadkarni A, Rajesh P, Ruch RJ, Pittman DL.

Mol Carcinog. 2009 Jul;48(7):586-91. doi: 10.1002/mc.20545.

PMID:
19347880
8.

A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.

Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen LA, Leminen A, Heikkilä P, Blomqvist C, Bützow R, Aittomäki K, Nevanlinna H.

J Med Genet. 2012 Jul;49(7):429-32. doi: 10.1136/jmedgenet-2012-100852. Epub 2012 May 31.

9.

A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer.

Shu XO, Cai Q, Gao YT, Wen W, Jin F, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1462-7.

10.

Germline mutation in the RAD51B gene confers predisposition to breast cancer.

Golmard L, Caux-Moncoutier V, Davy G, Al Ageeli E, Poirot B, Tirapo C, Michaux D, Barbaroux C, d'Enghien CD, Nicolas A, Castéra L, Sastre-Garau X, Stern MH, Houdayer C, Stoppa-Lyonnet D.

BMC Cancer. 2013 Oct 19;13:484. doi: 10.1186/1471-2407-13-484.

11.

Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.

Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC.

JAMA. 1998 Mar 25;279(12):915-21.

PMID:
9544765
12.

Rare variants in the ATM gene and risk of breast cancer.

Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM; BCFR; kConFab, Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G.

Breast Cancer Res. 2011 Jul 25;13(4):R73. doi: 10.1186/bcr2919.

13.

Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.

Thompson ER, Rowley SM, Sawyer S, kConfab, Eccles DM, Trainer AH, Mitchell G, James PA, Campbell IG.

PLoS One. 2013;8(1):e54772. doi: 10.1371/journal.pone.0054772. Epub 2013 Jan 25.

14.

Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.

Jakubowska A, Narod SA, Goldgar DE, Mierzejewski M, Masojć B, Nej K, Huzarska J, Byrski T, Górski B, Lubiński J.

Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):457-9.

15.

DNA-repair genetic polymorphisms and breast cancer risk.

Smith TR, Levine EA, Perrier ND, Miller MS, Freimanis RI, Lohman K, Case LD, Xu J, Mohrenweiser HW, Hu JJ.

Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1200-4.

16.

The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, Southey MC, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):439-43.

17.

The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1287-93.

18.

Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ.

Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-7.

19.

A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.

Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP.

Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60.

20.

Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.

Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, Malone KE, Mellemkjaer L, Borresen-Dale AL, Rosenstein BS, Teraoka SN, Diep AT, Smith SA, Capanu M, Reiner AS, Liang X, Gatti RA, Concannon P; WECARE Study Collaborative Group.

J Natl Cancer Inst. 2010 Apr 7;102(7):475-83. doi: 10.1093/jnci/djq055. Epub 2010 Mar 19.

Supplemental Content

Support Center